8-Cyclopropyl-3-propyl-2,6-dithioxanthine | 162278-99-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 8-Cyclopropyl-3-propyl-2,6-dithioxanthine
• 英文别名: 8-cyclopropyl-3-propyl-7H-purine-2,6-dithione
• CAS: 162278-99-1
• 化学式: C₁₁H₁₄N₄S₂
• 分子量: 266.391
• InChiKey: JYHDDQCKFOYZHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  108
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  8-Cyclopropyl-3-propyl-2,6-dithioxanthine 在 盐酸 作用下， 以 sodium hydroxide 、 二氯甲烷 、 水 、 丙酮 为溶剂， 生成 8-Cyclopropyl-3,7-dihydro-3-propyl-6-(pyridin-4-ylmethylamino)-2H-purine-2-thione
  参考文献：
  名称：

  Purine derivatives having phosphodiesterase IV inhibition activity

  摘要：

  该化合物的公式为：其中R3代表未支化或支化的未取代或取代的C1-8烷基，取代基可以是OH、烷氧基、CO2H、═NOH、═NOCONH2或═O；也可以是未取代或取代的C3-8环烷基，取代基可以是OH、烷氧基、CO2H、═NOH、═NOCONH2或═O；或者是未取代或取代的C4-8环烷烷基，其中环烷基部分可以是OH、烷氧基、CO2H、═NOH、═NOCONH2或═O；还可以是未取代或取代的芳基，取代基可以是Cl、NH2、烷基胺基、二烷基胺基、酰胺、C1-C8烷基酰胺、C1-C3二烷基酰胺、OH、烷氧基、HC═NOH、HC═NOCONH2、C1-C3烷基、苯基或苄基；芳基烷基（C1-4）；杂环烷基；杂环烷基烷基（C1-C4）；和杂芳基；R8代表H或未支化或支化的未取代或取代的C1-8烷基，取代基可以是OH、烷氧基、CO2H、═NOH、═NOCONH2或═O；也可以是未取代或取代的C3-8环烷基，取代基可以是OH、烷氧基、CO2H、═NOH、═NOCONH2或═O；或者是未取代或取代的C4-8环烷烷基，其中环烷基部分可以是OH、烷氧基、CO2H、═NOH、═NOCONH2或═O；还可以是未取代或取代的芳基，取代基可以是Cl、NH2、烷基胺基、二烷基胺基、酰胺、C1-C8烷基酰胺、C1-C3二烷基酰胺、OH、烷氧基、HC═NOH、HC═NOCONH2、C1-C3烷基、苯基或苄基；芳基烷基（C1-4）；杂环烷基；杂环烷基烷基（C1-C4）；和杂芳基。

  公开号：

  US06294541B1
• 作为产物：
  描述：

  8-cyclopropyl-3-propyl-2-thio-xanthine 、 甲烷 在 diphosphorus pentasulfide 作用下， 以 吡啶 、 sodium hydroxide 、 水 为溶剂， 生成 8-Cyclopropyl-3-propyl-2,6-dithioxanthine
  参考文献：
  名称：

  Purine derivatives having phosphodiesterase iv inhibition activity

  摘要：

  揭示了以下化合物：其中R3、R6a、R6b和R8如本文所述被取代。这些化合物对需要PDE IV抑制作用的患者有效。

  公开号：

  US06413975B1

文献信息

• [EN] NOVEL CHEMICAL COMPOUNDS HAVING PDE-IV INHIBITION ACTIVITY<br/>[FR] NOUVEAUX COMPOSES CHIMIQUES PRESENTANT UNE ACTIVITE D'INHIBITION DE LA PDE-IV (PHOSPHODIESTERASE IV)
  申请人：EURO-CELTIQUE S.A.

  公开号：WO1995000516A1

  公开（公告）日：1995-01-05

  (EN) Novel purine derivatives and their isoguanine and dithioxanthine precursor compounds are disclosed. These compounds have bronchial and tracheal relaxation and/or anti-inflammatory activity. The invention is also related to processes for their preparation, to pharmaceutical compositions containing them and to their medical use. In certain preferred embodiments, the invention relates to 3-substituted and 3,8-disubstituted 6-amino purine derivatives.(FR) On décrit de nouveaux dérivés de purine et leurs composés précurseurs à base d'isoguanine et de dithioxanthine. Ces composés présentent une activité de relaxation bronchique et trachéale et/ou anti-inflammatoire. L'invention concerne aussi leurs procédés de préparation, des compositions pharmaceutiques les contenant et leur utilisation médicale. Dans certaines variantes préférées, l'invention concerne des dérivés de 6-amino purine 3-substitués et 3,8 disubstitués.

  （中文）本发明揭示了新的嘌呤衍生物及其异鸟嘌呤和二硫黄黄质前体化合物。这些化合物具有支气管和气管松弛和/或抗炎活性。本发明还涉及它们的制备过程，含有它们的制药组合物以及它们的医疗用途。在某些优选实施例中，本发明涉及3-取代和3,8-二取代的6-氨基嘌呤衍生物。
• PDE IV inhibitors: "bis-compounds"
  申请人：Euro-Celtique, S.A.

  公开号：US05744473A1

  公开（公告）日：1998-04-28

  Novel compounds which are effective PDE IV inhibitors are disclosed. The compounds possess improved PDE IV inhibition as compared to theophylline or rolipram, with improved selectivity with regard to, e.g., PDE V inhibition. Also provided is a process of making compounds of Formula I. Compounds of the present invention are represented by Formula I: ##STR1## its pharmaceutically acceptable salts, hydrochloride salts, or prodrug forms thereof, wherein: X.sub.1a, X.sub.1b are independently selected from --NH and --N-lower alkyl; X.sub.2a, X.sub.2b are optionally present and are independently selected from S(O)n, O, CH.sub.2, and NH; P.sub.1a, P.sub.1b, P.sub.2a, P.sub.2b, P.sub.4a, and P.sub.4b are independently selected from N, or CH; R.sub.1a, R.sub.1b, R.sub.2a, R.sub.2b, R.sub.3a and R.sub.3b are independently selected from H, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 branched alkyl, C.sub.3 -C.sub.6 cycloalkyl, said alkyl groups being optionally substituted with halogen, aryl or heteroaryl group(s), said aryl and heteroaryl group(s) being optionally substituted with hydroxy, alkoxy, cycloalkoxy, halogen, alkyl, or cycloalkyl; and n is an integer from 0 to 2.

  本发明揭示了有效的PDE IV抑制剂新化合物。这些化合物相比茶碱或罗利帕姆具有更好的PDE IV抑制作用，并具有改善的选择性，例如对于PDE V的抑制作用。还提供了制备式I化合物的方法。本发明的化合物由式I表示：##STR1## 其中X.sub.1a，X.sub.1b独立地选自--NH和--N-较低烷基；X.sub.2a，X.sub.2b是可选的，且独立地选自S(O)n，O，CH.sub.2和NH；P.sub.1a，P.sub.1b，P.sub.2a，P.sub.2b，P.sub.4a和P.sub.4b独立地选自N或CH；R.sub.1a，R.sub.1b，R.sub.2a，R.sub.2b，R.sub.3a和R.sub.3b独立地选自H，C.sub.1-C.sub.6烷基，C.sub.3-C.sub.6支链烷基，C.sub.3-C.sub.6环烷基，所述烷基基团可选地被卤素，芳基或杂环芳基基团取代，所述芳基和杂环芳基基团可选地被羟基，烷氧基，环烷氧基，卤素，烷基或环烷基取代；n是0到2的整数。其中，其制药可接受的盐，盐酸盐或前药形式。
• Chemical compounds having PDE-IV inhibition activity
  申请人：Euro-Celtique, S.A.

  公开号：US05939422A1

  公开（公告）日：1999-08-17

  Disclosed is a compound of the formula (I): wherein R.sub.3, R.sub.6a and R.sub.8 are the same or different and represent a C.sub.2-8 alkyl which is unbranched or branched and unsubstituted or substituted; C.sub.3-8 cycloalkyl which is unsubstituted or substituted; C.sub.4-8 cycloalkylalkyl wherein the cycloalkyl portion is unsubstituted or substituted; aryl which is unsubstituted or substituted; aralkyl C.sub.1-4 ; heterocyclyl; and heterocyclylalkyl (C.sub.1 -C.sub.4) R.sub.6b represents H or R.sub.6a, or together R.sub.6b, N, and R.sub.6a make a C.sub.3 -C.sub.8 ring containing from one to three nitrogen atoms, from zero to two oxygen atoms, from zero to two sulfur atoms, which is optionally substituted; and where aryl is phenyl or naphthyl, the heterocyclyl is a 5, 6 or 7 membered ring including from one to three nitrogen atoms, and from zero to two oxygen atoms, from zero to two sulfur atoms, and can be substituted as in aryl on the carbons or nitrogens of that ring; or a pharmaceutically acceptable salt thereof.

  本发明揭示了一种化合物的结构式（I）：其中，R.sub.3、R.sub.6a和R.sub.8相同或不同，表示未支链或支链的C.sub.2-8烷基，未取代或取代；未取代或取代的C.sub.3-8环烷基；未取代或取代的C.sub.4-8环烷基烷基，其中环烷基部分未取代或取代；未取代或取代的芳基；未取代或取代的芳基烷基C.sub.1-4；杂环烷基；和杂环烷基烷基（C.sub.1-C.sub.4）；R.sub.6b表示H或R.sub.6a，或者R.sub.6b，N和R.sub.6a共同构成一个含有从1到3个氮原子，从0到2个氧原子，从0到2个硫原子的C.sub.3-C.sub.8环，该环可以选择性地被取代；其中，苯基或萘基的芳杂环为5、6或7成员环，包括从1到3个氮原子和从0到2个氧原子、从0到2个硫原子，并且可以在该环的碳或氮上像芳基一样被取代；或其药学上可接受的盐。
• 6-Amino purine derivatives having PDE-IV inhibition activity and intermediates
  申请人：Euroceltique S.A.

  公开号：EP0916672A1

  公开（公告）日：1999-05-19

  Novel purine derivatives and their isoguanine and dithioxanthine precursor compounds are disclosed. These compounds have bronchial and tracheal relaxation and/or anti-inflammatory activity. The invention is also related to processes for their preparation, to pharmaceutical compositions containing them and to their medical use. In certain preferred embodiments, the invention relates to 3-substituted and 3,8-disubstituted 6-amino purine derivatives.

  本研究公开了新型嘌呤衍生物及其异鸟嘌呤和二硫黄嘌呤前体化合物。这些化合物具有舒张支气管和气管和/或抗炎活性。本发明还涉及它们的制备工艺、含有它们的药物组合物及其医疗用途。在某些优选的实施方案中，本发明涉及 3-取代和 3,8-二取代的 6-氨基嘌呤衍生物。
• NOVEL CHEMICAL COMPOUNDS HAVING PDE-IV INHIBITION ACTIVITY
  申请人：Euroceltique S.A.

  公开号：EP0705265A1

  公开（公告）日：1996-04-10